Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that among Chinese males with male androgenic alopecia, combination therapy using topical minoxidil and nano-microneedle-assisted fibroblast growth factor significantly improved hair density, diameter, and follicular unit density over 16 weeks, outperforming individual treatments.

In this case report, the authors linked acute psoriasiform contact dermatitis of the forehead and scalp to a low-laser light cap, identifying DMDE in the fabric as a likely cause.

This study found that a twice-daily regimen of 5% minoxidil foam combined with a botanical hair solution significantly improved hair growth and appearance in men with mild to moderate androgenic alopecia over 12 weeks.

This study found that topical betamethasone dipropionate was more effective than topical latanoprost in reducing the area and promoting hair regrowth in patients with localized alopecia areata, though latanoprost was considered safer.

This study found that a 12-week regimen of 2% minoxidil combined with a botanical hair solution improved hair growth and patient satisfaction for female pattern hair loss, aiding treatment adherence.

This study found that the "pink tax" persists in topical minoxidil products, with foams marketed to women costing about 20% more than those for men, despite identical ingredients and an overall price increase since 2017.

This study observed that while both minoxidil and botanically-derived 5-alpha reductase inhibitors significantly increased hair count and diameter in women with female pattern hair loss, minoxidil was more effective, especially for greater hair diameter increases, but had more troublesome side effects.

In this randomized clinical trial, oral minoxidil was not superior to topical minoxidil in increasing hair density in men with androgenetic alopecia over 24 weeks, though photographic analysis suggested oral minoxidil may work better on the vertex area of the scalp.

This study compared the effectiveness of topical finasteride, oral finasteride, and topical minoxidil over 12 months in postmenopausal women with androgenetic alopecia, exploring their therapeutic effects on this population. Results are not reported in the abstract.

This study found that both Betasalic ointment and 5% minoxidil resulted in acceptable hair regrowth for patients with alopecia areata over a three-month period, with any adverse effects being transient.

Temporal triangular alopecia is a lifelong condition with hairless patches on the side of the head that may be present from birth.

In this study, minoxidil 2% produced satisfactory esthetical results in about 30% of patients, but placebo-treated subjects experienced increased hair counts without a cosmetic benefit, possibly due to seasonal variations and hair classification issues.

This article reviews current and prospective treatments for androgenetic alopecia, noting that minoxidil is the only approved topical therapy; it reports no new clinical results.

This exploratory pilot study found that topical sildenafil and minoxidil both significantly increased hair counts in male patients with androgenic alopecia, with varying effects at different scalp regions.

In this prospective study, combining 5% topical minoxidil with platelet rich plasma provided more significant improvements in hair parameters for male baldness than platelet rich plasma alone over six months.

This study highlights that topical ruxolitinib cream is FDA-approved for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients aged 12 and older, but its use in other skin conditions like frontal fibrosing alopecia remains under-researched and needs further exploration in clinical practice.

This study reports anagen hair loss four weeks after scalp surgeries, likely due to transient ischemia, and emphasizes the importance of informing patients about potential hair loss and recovery within three months.

This study found that the p.E402K mutation in the KRT86 gene is a hotspot in Chinese patients with monilethrix, and treatment with 5% topical minoxidil significantly improved hair density and quality.

In this case series, four African American women with treatment-resistant central centrifugal cicatricial alopecia showed scalp itch relief and significant hair regrowth after using a new botanical formula for 8 weeks to 1 year, with no adverse effects reported.

Topical Stemoxydine improves hair density in androgenetic alopecia with few side effects.

This study found that in patients with female androgenetic alopecia, mesodermal injection of 0.5% minoxidil was more effective in increasing hair density and improving hairline height than topical 2% minoxidil, with comparable safety over 16 weeks.

This review reports that vitamin D plays an important role in hair follicle development, with a negative correlation observed between serum vitamin D levels and female pattern hair loss, suggesting further research is needed before recommending vitamin D as a treatment.

In this study, the application of topical 1% spironolactone in patients with androgenetic alopecia significantly increased hair count and thickness in females and increased hair count in males, though not all hair types showed significant changes.

This study found that microneedling combined with 5% minoxidil significantly improved hair growth in patients with androgenetic alopecia compared to using 5% minoxidil alone, with headache and erythema being common side effects in both groups.

Hair loss treated with minoxidil, finasteride, laser/light, hair transplant, and scalp prostheses; more research needed for skin of color.

This study concluded that horizontal sections of scalp biopsy specimens provide more diagnostic information for male pattern androgenetic alopecia than vertical sections and can predict hair regrowth potential following topical minoxidil therapy.

This study demonstrated that hair follicles significantly expedite the absorption of caffeine through the skin compared to interfollicular pathways.

Minoxidil increases blood flow in balding scalps, possibly reversing hair loss.

This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.

This review provides an overview of scalp psoriasis treatments but presents no new clinical results; it highlights various options including coal tar, salicylic acid, corticosteroids, and vitamin D3 analogues.